<DOC>
	<DOC>NCT00548834</DOC>
	<brief_summary>The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.</brief_summary>
	<brief_title>Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Signs and Symptoms</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>male/female, 1875 years old, inclusive diagnosis of adultonset RA had active disease had received methotrexate on a stable dose of folic acid contraindication for methotrexate or antiTNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab Pegol</keyword>
</DOC>